



Vaccine injury following moderna COVID-19 vaccine: A case report

Abraham M Enyeji^{1*}; Sudhir Kathuria²; Brett Spencer Hammett¹; Tahirah Nimi¹; Harpal S Mangat³

¹Division of Community Medicine, Mercer University School of Medicine, Columbus, GA 31901, USA.

²Charter Radiology, Columbia, MD 21044, USA.

³Mangat & Kaur INC Germantown, MD 20876, USA.

Corresponding Author: Abraham M Enyeji

Division of Community Medicine, Mercer University School of Medicine, Columbus, GA, 31901, USA.

Email: enyeji_a@mercer.edu

Introduction

The global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to the widespread occurrence of Coronavirus Disease 2019 (COVID-19), affecting multiple body systems. In response, the United States Food and Drug Administration authorized the emergency use of the Moderna COVID-19 vaccine (mRNA-1273 SARS-CoV-2) at the end of 2020 [1]. While venous thromboembolism is rarely linked to mRNA vaccines, there have been reports of uncommon thrombotic events, including Vaccine-Induced Thrombotic Thrombocytopenia (VITT) and arterial thrombosis such as Central Retinal Artery Occlusion (CRAO), following the Moderna mRNA-1273 vaccination [2]. These events have been noted due to a temporal association between vaccination and the occurrence of CRAO [3]. This report discusses a case involving diplopia, atypical carotid artery occlusions, and coronary artery occlusion that appears to be linked to the Moderna COVID-19 vaccine.

Case presentation

A 65-year-old Caucasian male, previously in good health, presented with vertigo, lightheadedness, and diplopia that began the previous night at 11:23 PM. He reported that his vision initially became blurry and then progressed to double vision. He also experienced mild dysphagia, which began that night but allowed for the tolerance of liquids. Upon waking the next day, his symptoms had worsened, prompting his visit to the emergency room, where left internuclear ophthalmoplegia was identified via imaging. Additional complaints included loss of balance with unsteadiness while walking and stuttering, which were confirmed by his wife and son to be unusual for him. He denied chest pain, palpitations, chills, shortness of breath, aphasia, or syncope. Although he admitted to regular alcohol consumption, he denied any history of alcohol withdrawal symptoms and illicit drug use. His medical history included treatment for COVID-19 on May 23, 2023, with Kaletra, Hydroxychloroquine (HCQ), Pulmicort, famotidine, clarithromycin, and Benadryl. He received the Moderna COVID-19 vaccination on May 5 and June 2, 2023.

Abstract

Following the proliferation of the SARS-CoV-2 virus worldwide, there has been urgent demand for the rapid development of vaccines. Consequently, years following the identification of the virus, multiple vaccine candidates were formulated and authorized for distribution. In response to the rising number of individuals experiencing uncommon adverse effects post-vaccination, not explicitly outlined in product specifications, the Centers for Disease Control and Prevention introduced V-Safe, a real-time Vaccine Adverse Event Reporting System (VAERS), to meticulously monitor potential adverse effects arising from the vaccines. Given this context, we present a case of coronary artery occlusion and internuclear ophthalmoplegia following the administration of the Moderna COVID-19 mRNA vaccine. This case underscores the importance of closely monitoring patients reporting a variety of symptoms, such as chest discomfort and unclear vision or loss of vision post-vaccination, particularly if they do not respond to standard treatment.

Keywords: SARS-CoV-2 virus; Moderna COVID-19 vaccine; CT angiogram.

Article Details

Received: Oct 28, 2024

Accepted: Dec 23, 2024

Published: Dec 30, 2024

Annals of Cardiology - www.anncardiology.org

Enyeji AM et al. © All rights are reserved



Citation: Enyeji AM, Kathuria S, Spencer Hammett B, Nimi T, Mangat HS. Vaccine injury following moderna COVID-19 vaccine: A case report. Ann Cardiol. 2025; 1(1): 1003.

In the emergency room, his vitals indicated hypertension, with otherwise stable parameters. His EKG showed normal sinus rhythm at 73 bpm with an incomplete left bundle branch block. Carotid Doppler and CT angiography of the neck revealed 69% stenosis of the left carotid artery as shown in Figure 1 above, and less than 20% stenosis of the right carotid artery (Figure 2). He was started on Plavix and maintained on oral doses.




Figure 1: Showing a 69% stenosis of the left carotid artery with high flow velocity.

During his initial office visit, he presented with diplopia when looking outward horizontally and downward to the right. He also experienced difficulties typing and spelling, despite being a childhood spelling champion. His D-dimer level was elevated at 0.88 (normal range 0-0.49), and CRP was within normal limits at 1 (<1.0 mg/dL). His COVID-19 spike protein antibody level was initially >3385 Arbitrary Units per milliliter (AU/ml) (normal range <0.8 AU/ml).

A CT angiography of the heart revealed extensive moderate stenosis in the proximal left anterior descending coronary artery and severe stenosis in the mid left anterior descending coronary artery. Notably, the occlusion was in the mid artery with a clear view to the capillary walls. He underwent catheterization with stent implantation in the culprit lesion and was provided with an appropriate secondary preventive medication regimen.

An accompanying 3T MRI showed contrast enhancement in the right facial nerve with mastoid effusion, a condition associated with COVID-19 [4,5]. Effusions on the mastoid of COVID-19 patients, thickening of the facial nerve, and subarachnoid space closure on the facial nerve were noted (Figures 2, 3 & 4). He was started on ivermectin 13 mg for 10 days and subsequently every month. His diplopia resolved within a month, and his feet felt warmer.




Figure 2: Axial Flair image demonstrates focal lacunar ischemic lesions in right frontal lobe (arrows).



Figure 3: Axial T2 weighted image demonstrates multiple scattered foci of fluid signal (arrows) suggestive of mild right mastoid effusion.



Figure 4: Axial Post-contrast T1 weighted image demonstrates asymmetric enhancement involving mastoid segment of right facial nerve (arrow).

Discussion

This unusual severity of carotid occlusion, coupled with the patient's history of cardiovascular complications commonly associated with COVID-19, suggested a possible link. The hypercoagulable state seen in COVID-19 patients may result from systemic inflammation and endothelial injury induced by the virus, alongside increased pro-coagulant factors [8,9]. Autopsy studies have highlighted the high prevalence of thromboembolic events, reinforcing the idea that COVID-19 significantly affects coagulation pathways [10]. In our patient, the extensive occlusions observed in the left anterior descending artery, and the internuclear ophthalmoplegia were particularly concerning, especially given their history of SARS-CoV-2 vaccination, which may exacerbate thrombus formation. Previous authors have described the clinical manifestations and short-term prognosis of ocular motility disorders such as internuclear ophthalmoplegia [11,12].

which can enhance thrombotic conditions, particularly in narrowed arterial spaces, such as the severely stenosed left carotid artery in our patient. This potential for increased thrombogenic activity underscores the critical need for careful monitoring of anticoagulant therapy in the context of COVID-19. Conversely, ivermectin mitigates these risks by preventing the spike protein from interacting with host cell membranes, thereby reducing viral entry and replication [13].

Additionally, MRI findings in our patient indicated cranial nerve lesions associated with COVID-19. Previous studies have documented cranial nerve involvement, including anosmia linked to the olfactory bulb and facial nerve paralysis [14-16]. This raised concerns about potential vaccine injury, particularly given the evidence linking vaccine-induced inflammation and thrombosis [17].

The combination of confirmed thrombus formation in the coronary arteries via CT angiogram and elevated serum spike protein antibody levels supported the hypothesis of vaccine-induced thrombotic events, rather than simple plaque formation. Furthermore, the administration of ivermectin for over four months led to notable improvements in the patient's symptoms, with a documented reduction in COVID-19 spike protein levels from 3385 arbitrary units per milliliter (AU/ml) at presentation to 2699 AU/ml. This decline further illustrates the potential therapeutic benefits of ivermectin. Overall, these findings suggest that the occlusion was primarily caused by elevated viral spike protein rather than the conventional pathways associated with atherosclerotic disease.

Conclusion

In conclusion, this case highlights the significant risk of thrombotic events following vaccination with the Moderna COVID-19 vaccine, particularly in patients with preexisting conditions. The interplay between heparin and the spike protein underscores the need for careful monitoring and individualized treatment strategies in such cases. The observed cranial nerve lesions and visual defects emphasize the importance of being vigilant about neurological complications related to COVID-19 and its vaccination. Further research is crucial to elucidate the mechanisms behind vaccine-induced thrombosis and to develop guidelines that optimize patient outcomes while ensuring the safe administration of vaccines to vulnerable populations.

Declarations

Ethical considerations: Ethical considerations and consent are not applicable, as there were no relevant factors requiring them.

Consent to participate: The authors confirm that informed consent was obtained from all participants involved in this study.

Consent for publication: Informed consent was obtained from all subjects involved in the study.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability: For this case report, patient data, including laboratory findings and imaging studies, can be obtained from the authors upon request.

References

1. FDA. Emergency Use Authorization (EUA) for an Unapproved Product. 2021. <https://www.fda.gov/media/144434/download>
2. Chow SY, Hsu YR, Fong VH. Central retinal artery occlusion after Moderna mRNA-1273 vaccination. *Journal of the Formosan Medical Association*. 2022; 121(11): 2369 doi: 10.1016/j.jfma.2022.07.002
3. Houghton DE, Sullivan D, Maguire B. COVID-19 mRNA vaccines and thrombotic events: A review of current evidence. *Vaccine*. 2021; 39(45): 6486-6492.
4. Lima MA, Silva MTT, Araujo A. Peripheral facial nerve palsy associated with COVID-19. *Journal of neurovirology*. 2020; 26: 941-944. doi.org/10.1007/s13365-020-00912-6
5. Estakhr M, Tabrizi R, Borhani-Haghighi A. Is facial nerve palsy an early manifestation of COVID-19? A literature review. *The American Journal of the Medical Sciences*. 2022; 364(3): 264-273. doi.org/10.1016/j.amjms.2022.04.010
6. Paknahad S, Rajai H, Mahmoudi H. Cardiovascular Complications of COVID-19: A Systematic Review and Meta-Analysis. *American Journal of Cardiovascular Drugs*. 2023; 23: 121-134. doi.org/10.1016/j.hrtlng.2023.02.003
7. Parthenis DG, Karakasis CS, Voulgaris K, Anastasiou I. Common Carotid Artery Occlusion: Case Report and Review of the Literature. *Journal of Cardiovascular Surgery*. 2008; 49(4): 527-529.
8. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nature Reviews Cardiology*. 2020; 17(9): 543-558. doi:10.23750/abm.v92i5.12013
9. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) with myocardial injury and mortality. *JAMA cardiology*. 2020; 5(7): 751-753. doi:10.1001/jamacardio.2020.1105
10. Zheng Y, Lai X, Tan Y. Heparan Sulfate and Heparin Interact with Spike Glycoprotein of SARS-CoV-2 and Modulate the Virus Infection. *Thrombosis and Haemostasis*. 2021; 121(9): 1236-1244.
11. Park KA, Jeon H, Choi DG, Jung JH, Shin HJ, et al. Ocular motility disorders following coronavirus disease-19 vaccination. *Graefes Archive for Clinical and Experimental Ophthalmology*. 2023; 261(4): 1127-1139. Doi.org/10.1007/s00417-022-05888-z
12. Feizi M, Isen DR, Tavakoli M. Neuro-ophthalmic manifestations of coronavirus disease 2019 and its vaccination: A narrative review. *Journal of Ophthalmic & Vision Research*. 2023; 18(1): 113 doi: 10.18502/jovr.v18i1.12731
13. Low ZY, Yip AJW, Lal SK. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 2022; 1868(2): 166294. doi.org/10.1016/j.bba-dis.2021.166294
14. Aragão MFV, Leal MC, Cartaxo Filho OQ. Anosmia in COVID-19 associated with injury to the olfactory bulbs evident on MRI. *American Journal of Neuroradiology*. 2020; 41(9): 1703-1706. doi:https://doi.org/10.3174/ajnr.A6675
15. Corrêa DG, Hygino da Cruz LC, Lopes MC, et al. Magnetic Resonance Imaging of Brain Abnormalities in Patients with COVID-19. *Journal of Neuroimaging*. 2021; 31(1): 5-12.
16. Vargas-Gandica J, Winter D, Schnieder J, et al. Case Report: COVID-19 Associated with Miller-Fisher Syndrome and Facial Nerve Palsy-A Case Report. *Frontiers in Neurology*. 2020; 11: 835.
17. Pomara C, Sessa F, Ciaccio M. Postmortem findings in vaccine-induced thrombotic thrombocytopenia. *Haematologica*. 2021; 106(8): 2291-2293. doi:10.3324/haematol.2021.279075